Author:
Chapple Christopher R.,Cruz Francisco,Cardozo Linda,Staskin David,Herschorn Sender,Choudhury Nurul,Stoelzel Matthias,Heesakkers John,Siddiqui Emad
Reference27 articles.
1. Burkhard FC, Bosch R, Cruz F, et al. EAU guidelines on urinary incontinence in adults. Eur Urol. In press.
2. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia;Chapple;Expert Rev Clin Pharmacol,2017
3. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: comparison with placebo and tolterodine;Sebastianelli;Int J Urol,2018
4. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial;Khullar;Eur Urol,2013
5. Results of a randomized phase III trial of mirabegron in patients with overactive bladder;Nitti;J Urol,2013